Insulet's TV advertising for its Omnipod insulin pump began last year in a test run to gauge TV channel effectiveness for the brand. Now, seven commercials and almost $15 million later, the ads targeted at Type 1 and Type 2 diabetes patients are here to stay—at least through year-end. Insulet CEO and President Shacey Petrovic confirmed the decision recently during the company's 2020 year-end earnings call, citing new insights and increased awareness of Omnipod as reasons to continue the ads.